A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Open accessThe DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.
Abstract
Major advances in understanding the pathogenesis of inherited metabolic disease caused by mitochondrial DNA mutations have yet to translate into treatments of proven efficacy. Leber's hereditary optic neuropathy is the most common mitochondrial DNA disorder causing irreversible blindness in young adult life. Anecdotal reports support the use of idebenone in Leber's hereditary optic neuropathy, but this has not been evaluated in a randomized controlled trial. We conducted a 24-week multi-centre double-blind, randomized, placebo-controlled trial in 85 patients with Leber's hereditary optic neuropathy due to m.3460G>A, m.11778G>A, and m.14484T>C or mitochondrial DNA mutations. The active drug was idebenone 900 mg/day. The primary end-point was the best recovery in visual acuity. The main secondary end-point was the change in best visual acuity. Other secondary end-points were changes in visual acuity of the best eye at baseline and changes in visual acuity for both eyes in each patient. Colour-contrast sensitivity and retinal nerve fibre layer thickness were measured in subgroups. Idebenone was safe and well tolerated. The primary end-point did not reach statistical significance in the intention to treat population. However, post hoc interaction analysis showed a different response to idebenone in patients with discordant visual acuities at baseline; in these patients, all secondary end-points were significantly different between the idebenone and placebo groups. This first randomized controlled trial in the mitochondrial disorder, Leber's hereditary optic neuropathy, provides evidence that patients with discordant visual acuities are the most likely to benefit from idebenone treatment, which is safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therapy for LHON has been restricted to supportive measures rather than cure.10”
From Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1/2 Clinical Trial (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Current treatments for LHON remain inadequate.8 Idebenone (Raxone, Santhera GmbH) was granted market authorization by the European Medicines Agency (EMA) for the treatment of LHON under exceptional circumstances, 9,10 but its benefits are limited.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Linear mixed models for longitudinal data
(2000) · Springer Series in Statistics · doi:10.1007/b98969 · Cited by 818
Lange, C., Feltgen, N., Junker, B., Schulze-Bonsel, K., & Bach, M. (2009) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0926-0 · Cited by 626 · cited 1×
“Patients only able to count fingers, detect hand motion or light perception were assigned logMAR values 2.0, 2.3 and 2.6, respectively (Lange et al., 2009).”
BackgroundInfluentialRiordan-Eva, P., Sanders, M. D., Govan, G. G., Sweeney, M. G., Costa, J. D., & Harding, A. E. (1995) · Brain · doi:10.1093/brain/118.2.319 · Cited by 490
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Man, P. Y. W., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 483 · cited 1×
“Leber’s hereditary optic neuropathy (LHON; MIM 535000) is the most common mitochondrial disorder affecting more than 1:14 000 males (Man et al., 2003).”
BackgroundSelf-citationNewman, N. J., Lott, M. T., & Wallace, D. C. (1991) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)76784-4 · Cited by 403 · cited 3×
“Most remain legally blind, are unable to drive a motor vehicle, and are unable to find employment (Newman et al., 1991; Riordan-Eva et al., 1995; Nikoskelainen et al., 1996).”
BackgroundResultInfluentialThe epidemiology of mitochondrial disorders—past, present and future
Schaefer, A. M., Taylor, R. W., Turnbull, D. M., & Chinnery, P. F. (2004) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2004.09.005 · Cited by 396 · cited 1×
“Inherited disorders of mitochondrial energy metabolism are a major cause of metabolic disease affecting more than 1/5000 of the population (Schaefer et al., 2004).”
BackgroundSelf-citationBARBONI, P., SAVINI, G., VALENTINO, M., MONTAGNA, P., CORTELLI, P., DENEGRI, A., SADUN, F., BIANCHI, S., LONGANESI, L., & ZANINI, M. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.06.034 · Cited by 247 · cited 14×
“Leber’s hereditary optic neuropathy (LHON; MIM 535000) is the most common mitochondrial disorder affecting more than 1:14 000 males (Man et al., 2003).”
BackgroundInfluential
Research works printed but not linked: 1
- Harding AE Sweeney MG Govan GG Riordan-Eva P Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation Am J Hum Genet 1995 57 77 86 7611298 PMC1801226
Cited by
Items 101–200 of 574
Mitochondrial disorders: aetiologies, models systems, and candidate therapies
Farrar, G. J., Chadderton, N., Kenna, P. F., & Millington‐Ward, S. (2013) · Trends in Genetics · doi:10.1016/j.tig.2013.05.005 · Cited by 67
Mitochondrial diseases in adults
Morgia, C. L., Maresca, A., Caporali, L., Valentino, M. L., & Carelli, V. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13064 · Cited by 65
Angebault, C., Guéguen, N., Desquiret‐Dumas, V., Chevrollier, A., Guillet, V., Verny, C., Cassereau, J., Ferré, M., Miléa, D., Amati‐Bonneau, P., et al. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-557 · Cited by 58
“A recent randomized controlled trial in 85 patients with LHON showed that patients with discordant visual acuities were the most likely to benefit from idebenone treatment [8].”
BackgroundMitochondrial optic neuropathies: our travels from bench to bedside and back again
Sadun, A. A., Morgia, C. L., & Carelli, V. (2013) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12086 · Cited by 57
“The most common and prototypic mitochondrial disorder is probably LHON.12,13 LHON is due to mtDNA point mutations affecting complex I leading to pathogenic impairment of OXPHOS.”
BackgroundInfluentialA Review of Mitochondrial Optic Neuropathies: From Inherited to Acquired Forms
Pilz, Y. L., Bass, S. J., & Sherman, J. (2016) · Journal of Optometry · doi:10.1016/j.optom.2016.09.003 · Cited by 59
The KHENERGY Study: Safety and Efficacy of KH 176 in Mitochondrial m.3243A>G Spectrum Disorders
Janssen, M. C. H., Koene, S., de Laat, P., Hemelaar, P., Pickkers, P., Spaans, E., Beukema, R. J., Beyrath, J., Groothuis, J. T., Verhaak, C. M., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1197 · Cited by 63
“Because cellular reduction–oxidation (redox) imbalance has shown to play a key role in the pathogenesis of many of the clinical manifestations of mitochondrial diseases,(11,12) many studies and clinical trials have attempted to manipulate reactive oxygen species levels in cells, animals, or patients with mitochondrial…”
BackgroundMitochondrial Targeting of Probes and Therapeutics to the Powerhouse of the Cell
Ma, C., Xia, F., & Kelley, S. O. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00470 · Cited by 64
Retinal Ganglion Cell Dysfunction in Asymptomatic G11778A: Leber Hereditary Optic Neuropathy
Guy, J., Feuer, W. J., Porciatti, V., Schiffman, J., Abukhalil, F., Vandenbroucke, R., Rosa, P. R., & Lam, B. L. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13365 · Cited by 54
Vignal-Clermont, C., Girmens, J.-F., Audo, I., Said, S. M., Errera, M.-H., Plaine, L., O’Shaughnessy, D., Taiel, M., & Sahel, J.-A. (2021) · BioDrugs · doi:10.1007/s40259-021-00468-9 · Cited by 51
“Therapeutic options for adolescent and adult patients with LHON are currently limited to idebenone, and its benefits in patients with ND4 LHON are limited [19, 20].”
BackgroundInfluentialKlopstock, T., Priglinger, C., Yılmaz, A., Kornblum, C., Distelmaier, F., & Prokisch, H. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0251 · Cited by 76
“Based on the results of a randomized controlled trial (14) and an expanded access program (15), conditional approval was granted in the European Union (EU) in 2015 for the drug idebenone (3 × 300 mg/day) (evidence level Ib, grade A recommendation [8]).”
Self-citationYu‐Wai‐Man, P., Carelli, V., Newman, N. J., Silva, M. J., Linden, A., Stavern, G. V., Szaflik, J. P., Banik, R., Lubiński, W., Pemp, B., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101437 · Cited by 70
“23,24 Conclusions LEROS confirmed the benefit of idebenone in LHON, including in the chronic phase (1–5 years since onset).”
InfluentialSelf-citationMitochondria in Retinal Ganglion Cells: Unraveling the Metabolic Nexus and Oxidative Stress
Yang, T.-H., Kang, E. Y., Lin, P., Yu, B. B.-C., Wang, J. H.-H., Chen, V., & Wang, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168626 · Cited by 67
“No severe AEs reported [242].”
BackgroundCwerman-Thibault, H., Augustin, S., Ellouze, S., Sahel, J.-A., & Corral-Debrinski, M. (2014) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2013.11.011 · Cited by 49
Mitochondrial optic neuropathies
Carelli, V., Morgia, C. L., & Yu‐Wai‐Man, P. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-12-821751-1.00010-5 · Cited by 57
Self-citationJaber, S. M., Ge, S. X., Milstein, J. L., VanRyzin, J. W., Waddell, J., & Polster, B. M. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1632-17.2020 · Cited by 48
“Idebenone was recently approved in Europe for the treatment of LHON and mitigates loss of visual acuity (Klopstock et al., 2011; Lyseng-Williamson, 2016).”
BackgroundLeber hereditary optic neuropathy—new insights and old challenges
Sundaramurthy, S., Selvakumar, A., Ching, J., Dharani, V., Sarangapani, S., & Yu‐Wai‐Man, P. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04993-1 · Cited by 54
Self-citationKoene, S., Spaans, E., Bortel, L. M. V., Lancker, G. V., Delafontaine, B., Badilini, F., Beyrath, J., & Smeitink, J. A. M. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0715-0 · Cited by 49
“The latter has been subject of many studies and clinical trials [8, 9], since it has been recognised that cell redox imbalance play a key role in the pathogenesis of many of the clinical manifestations of mitochondrial diseases [5, 10–12].”
BackgroundDNAJC30 defect: a frequent cause of recessive Leber hereditary optic neuropathy and Leigh syndrome
Stenton, S. L., Tesařová, M., Sheremet, N. L., Catarino, C. B., Carelli, V., Ciara, E., Curry, K., Engvall, M., Fleming, L. R., Freisinger, P., et al. (2022) · Brain · doi:10.1093/brain/awac052 · Cited by 50
“However, with the approval of idebenone by the European Medicines Agency, recovery rates are now reported up to 46%.(7,9,10) Until recently, LHONwas considered to be exclusivelymaternally inherited,with 95%of familial cases reported to bedue topathogenic variants in themitochondrial genome (mtDNA) affecting subunits o…”
Self-citationSecondary Post-Geniculate Involvement in Leber’s Hereditary Optic Neuropathy
Rizzo, G., Tozer, K. R., Tonon, C., Manners, D. N., Testa, C. M., Malucelli, E., Valentino, M. L., Morgia, C. L., Barboni, P., Randhawa, R. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050230 · Cited by 46
“Recently, it has been demonstrated that administration of idebenone may also increase the rate of visual function recovery [4,5].”
BackgroundIdebenone increases chance of stabilization/recovery of visual acuity in OPA1‐dominant optic atrophy
Romagnoli, M., Morgia, C. L., Carbonelli, M., Vito, L. D., Amore, G., Zenesini, C., Cascavilla, M. L., Barboni, P., & Carelli, V. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51026 · Cited by 46
Yamada, Y., Somiya, K., Miyauchi, A., Osaka, H., & Harashima, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-64322-8 · Cited by 47
Arend, N., Wertheimer, C. M., Laubichler, P., Wolf, A., Kampik, A., & Kernt, M. (2015) · Ophthalmologica · doi:10.1159/000381726 · Cited by 47
Self-citationModeling mitochondrial DNA diseases: from base editing to pluripotent stem‐cell‐derived organoids
Tolle, I., Tiranti, V., & Prigione, A. (2023) · EMBO Reports · doi:10.15252/embr.202255678 · Cited by 44
“The antioxidant drug Idebenone has been officially approved for the treatment of LHON patients by the European Medicines Agency (EMA; Klopstock et al , 2011).”
Mitochondrial dysfunction in optic neuropathies: animal models and therapeutic options
Carelli, V., Morgia, C. L., & Sadun, A. A. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835c5f0b · Cited by 41
Cardiovascular Manifestations of Mitochondrial Disease
Duran, J. M., Martinez, A., & Adler, E. A. (2019) · Biology · doi:10.3390/biology8020034 · Cited by 45
Developments in the Treatment of Leber Hereditary Optic Neuropathy
Chen, B. S., Yu‐Wai‐Man, P., & Newman, N. J. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01246-y · Cited by 44
Self-citationTreatment of Mitochondrial Disorders: Antioxidants and Beyond
Enns, G. M. (2014) · Journal of Child Neurology · doi:10.1177/0883073814538509 · Cited by 43
“These findings led to the first randomized, controlled clinical trial in this disease.(57) Eighty-five patients with Leber hereditary optic neuropathy who had pathogenic mitochondrial DNA mutations (m.”
BackgroundInfluentialTargeting mitochondrial function to treat optic neuropathy
Gueven, N., Nadikudi, M., Daniel, A., & Chhetri, J. (2016) · Mitochondrion · doi:10.1016/j.mito.2016.07.013 · Cited by 41
Treatment strategies for Leber hereditary optic neuropathy
Jurkute, N., Harvey, J., & Yu-Wai-Man, P. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000646 · Cited by 38
“Patients were randomised in a 2:1 ratio in favour of idebenone and a dose of 300mg three times a day was used over a treatment period of 24 weeks [15,16].”
MethodSelf-citationThe m.13051G>A mitochondrial DNA mutation results in variable neurology and activated mitophagy
Dombi, E., Diot, A., Morten, K., Carver, J., Lodge, T., Fratter, C., Ng, Y. S., Liao, C., Muir, R., Blakely, E. L., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002688 · Cited by 37
Self-citationEndocrine Manifestations and New Developments in Mitochondrial Disease
Ng, Y. S., Lim, A. Z., Panagiotou, G., Turnbull, D. M., & Walker, M. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab036 · Cited by 48
Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm
Lenaers, G., Beaulieu, C., Charif, M., Gerber, S., Kaplan, J., & Rozet, J. (2023) · Brain · doi:10.1093/brain/awad131 · Cited by 43
“Oral delivery of idebenone has provided a significant visual acuity improvement for half of the individuals who received the treatment.(18,19) Importantly, arLHON patients carrying DNAJC30 mutations displayed a significantly higher ratio of visual improvement (up to 81%) after idebenone treatment (Table 3).”
BackgroundLee, H., Park, J.-H., & Hoe, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.749336 · Cited by 54
Emerging aspects of treatment in mitochondrial disorders
Rahman, S. (2015) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-015-9855-3 · Cited by 40
Gene therapy for mitochondrial disorders
Keshavan, N., Minczuk, M. A., Viscomi, C. F., & Rahman, S. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12699 · Cited by 43
“Overall, the trials have demonstrated an improvement of visual acuity in LHON eyes carrying the m.11778G>A mtDNA pathogenic variant treated with AAV2 gene therapy surpassing that expected from the natural history of the disease.”
BackgroundInfluentialFiebiger, S. M., Bros, H., Grobosch, T., Janssen, A., Chanvillard, C., Paul, F., Dörr, J., Millward, J. M., & Infante‐Duarte, C. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.07.002 · Cited by 37
“Idebenone appears to be clinically effective in diseases that are caused primarily by mitochondrial dysfunction, such as Friedreich ataxia or Leber's hereditary optic neuropathy (Di Prospero et al., 2007; Klopstock et al., 2011; Heitz et al., 2012; Rudolph et al., 2013).”
BackgroundOptic neuropathy in methylmalonic acidemia and propionic acidemia
Alvarez, L. M., Jameson, E., Parry, N. R. A., Lloyd, C., & Ashworth, J. L. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-306798 · Cited by 35
Is there treatment for Leber hereditary optic neuropathy?
Peragallo, J. H., & Newman, N. J. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000212 · Cited by 41
Mitochondrial disorders and drugs: what every physician should know
Orsucci, D., Ienco, E. C., Siciliano, G., & Mancuso, M. (2019) · Drugs in Context · doi:10.7573/dic.212588 · Cited by 37
Therapeutic Strategies for Mitochondrial Disorders
Finsterer, J., & Bindu, P. S. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.06.023 · Cited by 36
Oral and Systemic Photoprotection
González, S., Gilaberte, Y., & Juarranz, Á. (2016) · Springer eBooks · doi:10.1007/978-3-319-29382-0_22 · Cited by 39
Augustyniak, J., Lenart, J., Zychowicz, M., Stępień, P. P., & Bużańska, L. (2017) · Biogerontology · doi:10.1007/s10522-017-9718-4 · Cited by 34
“Idebenone was tested with varying degrees of success in Friedreich’s ataxia (Parkinson et al. 2013), Leber hereditary optic neuropathy (LHON) (Klopstock et al. 2011), mitochondrial encephalomyopathy (MELAS) (Napolitano et al. 2000), Duchenne muscular dystrophy (DELOS) (Buyse et al. 2015), multiple sclerosis (Villoslad…”
Clinical syndromes associated with mtDNA mutations: where we stand after 30 years
Carelli, V., & Morgia, C. L. (2018) · Essays in Biochemistry · doi:10.1042/ebc20170097 · Cited by 41
Crisafulli, S., Sultana, J., Ingrasciotta, Y., Addis, A., Cananzi, P., Cavagna, L., Conter, V., D’Angelo, G., Ferrajolo, C., Mantovani, L. G., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1614165 · Cited by 35
“visual acuity 24 weeks after the start of the study; no statistically significant difference between the two groups was observed although results were more positive for the secondary end-points [25].”
ResultTheodorou-Kanakari, A., Karampitianis, S., Karageorgou, V., Kampourelli, E., Kapasakis, E., THEODOSSIADIS, P. G., & Chatziralli, I. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0776-z · Cited by 37
Pemp, B., Kircher, K., & Reitner, A. (2019) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-019-04444-6 · Cited by 35
Clinical and electrophysiology findings in Slovene patients with Leber hereditary optic neuropathy
Jarc-Vidmar, M., Tajnik, M., Brecelj, J., Fakin, A., Šuštar, M., Naji, M., Stirn-Kranjc, B., Glavač, D., & Hawlina, M. (2015) · Documenta Ophthalmologica · doi:10.1007/s10633-015-9489-7 · Cited by 35
“Treatment is generally ineffective, and a randomized placebo-controlled study showed that idebenone (analog of Coenzyme Q10) had no statistically significant effect of improving visual function in patients with LHON [7].”
BackgroundSmith, T. G., Seto, S., Ganne, P., & Votruba, M. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.01.042 · Cited by 35
“…and correlate with modest clinical score improvements in patients with Friedreich’s ataxia and Leber’s hereditary optic neuropathy (Di Prospero et al., 2007; Bodmer et al., 2009; Kutz et al., 2009; Carelli et al., 2011; Klopstock et al., 2011; Parkinson et al., 2013; Buyse et al., 2015).”
BackgroundPemp, B., Mitsch, C., Kircher, K., & Reitner, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010151 · Cited by 34
“The beneficial use of idebenone in LHON has been supported by results from two controlled studies [9,10] and from a subsequent expanded access program [11], which led to its approval for this hitherto untreatable mitochondrial disease.”
BackgroundResultTreatment of Leber hereditary optic neuropathy
Newman, N. J. (2011) · Brain · doi:10.1093/brain/awr192 · Cited by 33
Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy
Yu‐Wai‐Man, P., Newman, N. J., Biousse, V., Carelli, V., Moster, M. L., Vignal‐Clermont, C., Klopstock, T., Sadun, A. A., Sergott, R. C., Hage, R., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.5375 · Cited by 41
Self-citationRecent advances in mitochondrial diseases: From molecular insights to therapeutic perspectives
Aldossary, A. M., Tawfik, E. A., Alomary, M. N., Alsudir, S. A., Alfahad, A. J., Alshehri, A. A., Almughem, F. A., Mohammed, R. Y., & Alzaydi, M. M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.05.011 · Cited by 42
“LHON, caused by abnormalities in the mitochondrial encoded MT-ND4 gene, is the only primary mitochondrial disease currently undergoing active clinical gene therapy trials (Slone and Huang, 2020).”
InfluentialMouse Studies to Shape Clinical Trials for Mitochondrial Diseases: High Fat Diet in Harlequin Mice
Schiff, M., Bénit, P., El‐Khoury, R., Schlemmer, D., Benoist, J., & Rustin, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028823 · Cited by 34
“While we still attempt to understand what could confer dietsensibility to a subset of animals, this suggests that individual therapeutic response is a key-feature of mt disease as reported recently in Leber Hereditary Optic Neuropathy [38].”
BackgroundDrugs and mitochondrial diseases: 40 queries and answers
Mancuso, M., Orsucci, D., Filosto, M., Simoncini, C., & Siciliano, G. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.657177 · Cited by 36
“Very recently, a 24-week multicenter double-blind, randomized, placebocontrolled trial was performed on 85 patients with Leber hereditary optic neuropathy [32].”
BackgroundIdebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition
Tomilov, A. A., Allen, S. A., Hui, C. K., Bettaieb, A., & Cortopassi, G. A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.024 · Cited by 32
Next-generation sequencing of mitochondrial targeted AAV transfer of human ND4 in mice.
Yu, H., Mehta, A., Wang, G., Hauswirth, W. W., Chiodo, V. A., Boye, S. L., & Guy, J. R. (2013) · PubMed Central · Cited by 33
Thouin, A., Griffiths, P. G., Hudson, G., Chinnery, P. F., & Yu‐Wai‐Man, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063446 · Cited by 30
“Although no visual recovery occurred in the left eye, the natural history could have been positively influenced by the initiation of idebenone treatment, which has shown promise as a possible neuroprotective agent in a recently completed randomised placebo-controlled trial [17].”
BackgroundSelf-citationIdebenone does not inhibit disability progression in primary progressive MS
Kosa, P. F., Wu, T., Phillips, J., Leinonen, M., Masvekar, R., Komori, M., Wichman, A., Sandford, M., & Bielekova, B. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102434 · Cited by 34
“This mechanism explains efficacy of idebenone in Leber’s hereditary optic neuropathy, a genetic dysfunction of ECT complex I (Klopstock et al., 2011).”
BackgroundSelf-citationDiffusion Tensor Imaging Mapping of Brain White Matter Pathology in Mitochondrial Optic Neuropathies
Manners, D. N., Rizzo, G., Morgia, C. L., Tonon, C., Testa, C. M., Barboni, P., Malucelli, E., Valentino, M. L., Caporali, L., Strobbe, D., et al. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4272 · Cited by 29
“The number of voxels with a significant difference in terms of diffusivity parameters was considerably higher in patients with OPA1-DOA than in those with LHON.”
ResultToward a therapy for mitochondrial disease
Viscomi, C. F. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160085 · Cited by 32
Carelli, V., Newman, N. J., Yu‐Wai‐Man, P., Biousse, V., Moster, M. L., Subramanian, P. S., Vignal‐Clermont, C., Wang, A.-G., Donahue, S. P., Leroy, B. P., et al. (2022) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00611-x · Cited by 30
“Idebenone has been shown to improve the visual outcomes of patients with LHON in randomised and real-word settings [19–21].”
BackgroundSelf-citationTakemura, H., Ogawa, S., Mezer, A., Horiguchi, H., Miyazaki, A., Matsumoto, K., Shikishima, K., Nakano, T., & Masuda, Y. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101826 · Cited by 32
Leber’s hereditary optic neuropathy: Update on current diagnosis and treatment
Esmaeil, A., Ali, A., & Behbehani, R. S. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2022.1077395 · Cited by 38
“RHODOS Trial NCT00747487 (78) 24-week double-blinded RCT.”
Gene Therapies for the Treatment of Leber Hereditary Optic Neuropathy
Sahel, J., Newman, N. J., Yu‐Wai‐Man, P., Vignal‐Clermont, C., Carelli, V., Biousse, V., Moster, M. L., Sergott, R. C., Klopstock, T., Sadun, A. A., et al. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000364 · Cited by 30
Self-citationKernt, M., Arend, N., Buerger, A., Mann, T., Haritoglou, C., ULBIG, M. W., Kampik, A., & Hirneiß, C. (2013) · Journal of Glaucoma · doi:10.1097/ijg.0b013e31824caf90 · Cited by 29
Self-citationPerspectives of mitochondrial medicine
Zorov, D. B., Исаев, Н. К., Plotnikov, E. Y., Silachev, D. N., Zorova, L. D., Pevzner, I. B., Morosanova, M. A., Jankauskas, S. S., Zorov, S. D., & Babenko, V. А. (2013) · Biochemistry (Moscow) · doi:10.1134/s0006297913090034 · Cited by 30
Antioxidant activity of idebenone-loaded neutral and cationic solid–lipid nanoparticles
Leonardi, A., Crascì, L., Panico, A., & Pignatello, R. (2014) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2014.915572 · Cited by 30
Levin, L. A. (2015) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000250 · Cited by 28
Advances in drug therapy for mitochondrial diseases
Zhang, L., Zhang, Z., Khan, A., Zheng, H., Yuan, C., & Jiang, H. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.113 · Cited by 27
Retractedvan Everdingen, J. A. M., Pott, J. W. R., Bauer, N. J. C., Krijnen, A. M., Lushchyk, T., & Wubbels, R. J. (2022) · Acta Ophthalmologica · doi:10.1111/aos.15153 · Cited by 28
“Since then, the previously reported beneficial effect of idebenone on recovery and preservation of vision (Klopstock et al. 2011) has been confirmed by two other studies: the real-world expanded access programme (EAP) in a mainly Western setting (Catarino et al.”
BackgroundResultMashima, Y., Kigasawa, K., Shinoda, K., Wakakura, M., & Oguchi, Y. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0583-3 · Cited by 28
“The dose of idebenone (Avan®) was 90 mg/day, which is one-tenth the dose of 900 mg/day of idebenone (Raxone®) in the clinical trial in Europe [20, 21].”
BackgroundInfluentialLeber Hereditary Optic Neuropathy—Light at the End of the Tunnel?
Kim, U. S., Jurkutė, N., & Yu‐Wai‐Man, P. (2019) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2018293 · Cited by 36
Self-citationKhaghani, F., Hemmati, M., Ebrahimi, M., & Salmaninejad, A. (2024) · Current Genomics · doi:10.2174/0113892029308327240612110334 · Cited by 28
Therapeutic Effects of Idebenone on Leber Hereditary Optic Neuropathy
Zhao, X., Zhang, Y., Lü, L., & Yang, H. (2020) · Current Eye Research · doi:10.1080/02713683.2020.1736307 · Cited by 28
“10,12,13 Another study found that idebenone did not prevent or postpone the involvement of the second eye.”
BackgroundThe Role of Citicoline and Coenzyme Q10 in Retinal Pathology
López, C. G., García-López, V., Matamoros, J. A., Fernández‐Albarral, J. A., Salobrar‐García, E., de Hoz, R., López‐Cuenca, I., Sánchez-Puebla, L., Ramirez, J. M., Ramirez, A. I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065072 · Cited by 34
“[70] Humans (LHON) Raxone (900 mg/day) ↑ VA ↑ Tritan color contrast”
BackgroundResultVIGNAL-CLERMONT, C., YU-WAI-MAN, P., NEWMAN, N. J., CARELLI, V., MOSTER, M. L., BIOUSSE, V., SUBRAMANIAN, P. S., WANG, A.-G., DONAHUE, S. P., LEROY, B. P., et al. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.11.026 · Cited by 25
Self-citationCurrent and Future Landscape in Genetic Therapies for Leber Hereditary Optic Neuropathy
Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2023) · Cells · doi:10.3390/cells12152013 · Cited by 30
“Its treatment efficiency is controversial; effective in some patients but failed in others [74].”
BackgroundThe Progress of Gene Therapy for Leber's Optic Hereditary Neuropathy
Zhang, Y., Tian, Z., Yuan, J., Liu, C. X., Liu, H. L., Qi, S., & Li, B. (2018) · Current Gene Therapy · doi:10.2174/1566523218666171129204926 · Cited by 25
“11778G>A had the least vision recovery [2, 11, 28, 45].”
Sitarz, K. S., Chinnery, P. F., & Yu‐Wai‐Man, P. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0260-0 · Cited by 30
Self-citationFichi, G., Naef, V., Barca, A., Longo, G., Fronte, B., Verri, T., Santorelli, F. M., Marchese, M., & Petruzzella, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102409 · Cited by 29
“Currently, idebenone was proposed as a first-line therapy in Leber’s hereditary optic neuropathy (LHON) syndrome because its capacity to improve visual defects in a subset of patients [121,122].”
BackgroundBorrelli, E., Bandello, F. M., Boon, C. J. F., Carelli, V., Lenaers, G., Reibaldi, M., Sadda, S. R., Sadun, A. A., Sarraf, D., Yu‐Wai‐Man, P., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101264 · Cited by 28
Self-citationMitochondrial disorders of the retinal ganglion cells and the optic nerve
Finsterer, J., Mancuso, M., Pareyson, D., Burgunder, J., & Klopstock, T. (2017) · Mitochondrion · doi:10.1016/j.mito.2017.10.003 · Cited by 25
Self-citationMoon, Y., Kim, U. S., Han, J., Ahn, H., & Lim, H. T. (2019) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000830 · Cited by 24
OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets
Wong, D., Harvey, J. P., Jurkutė, N., Thomasy, S. M., Moosajee, M., Yu‐Wai‐Man, P., & Gilhooley, M. J. (2023) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001830 · Cited by 27
“Idebenone was approved by the European Medicines Agency for the treatment of LHON after acute visual loss (93,94).”
BackgroundSelf-citationAleo, S. J., Dotto, V. D., Romagnoli, M., Fiorini, C., Capirossi, G., Peron, C., Maresca, A., Caporali, L., Capristo, M., Tropeano, C. V., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101383 · Cited by 29
“16,17,21,24,25 Unfortunately, about half of LHON patients remain unresponsive, and there is no clear explanation for why idebenone may be ineffective in these patients.”
BackgroundSelf-citationLeber hereditary optic neuropathy — Historical report in comparison with the current knowledge
Piotrowska-Nowak, A., Korwin, M., Bartnik, E., & Tońska, K. (2014) · Gene · doi:10.1016/j.gene.2014.09.048 · Cited by 24
Gropman, A. L., Uittenbogaard, M. N., & Chiaramello, A. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2023.e00311 · Cited by 28
“Results were encouraging but mixed in terms of stopping the worsening of visual loss [143 – 145].”
ResultTarnopolsky, M. A. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001182 · Cited by 37
Sabet-Peyman, E. J., Khaderi, K. R., & Sadun, A. A. (2012) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e318241da45 · Cited by 21
Ishikawa, H., Masuda, Y., Ishikawa, H., Shikisima, K., Goseki, T., Kezuka, T., Terao, M., Miyazaki, A., Matsumoto, K., Nishikawa, H., et al. (2020) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-020-00789-2 · Cited by 20
Clinical Overview of Leber Hereditary Optic Neuropathy
Stramkauskaitė, A., Povilaityte, I., Glebauskienė, B., & Liutkevičienė, R. (2022) · Acta medica Lituanica · doi:10.15388/amed.2022.29.1.19 · Cited by 24
“Idebenone 300 mg 3 times daily rarely causes adverse symptoms, but the most common side effects include nasopharyngitis, headache, cough, and dizziness [63].”
BackgroundTherapies in inborn errors of oxidative metabolism
Schiff, M., Bénit, P., Jacobs, H. T., Vockley, J., & Rustin, P. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.04.006 · Cited by 23
Chemical and technological delivery systems for idebenone: a review of literature production
Carbone, C., Pignatello, R., Musumeci, T., & Puglisi, G. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.724396 · Cited by 21
“More recently, IDE efficacy in Leber’s hereditary optic neuropathy (LHON) patients has been reported in a double-blind placebo-controlled randomized trial [23].”
BackgroundToxic-Metabolic and Hereditary Optic Neuropathies
Oliveira, C. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000769 · Cited by 24
Leber’s Hereditary Optic Neuropathy as a Promising Disease for Gene Therapy Development
Karaarslan, C. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01113-2 · Cited by 21
Newman, N. J., Biousse, V., Yu‐Wai‐Man, P., Carelli, V., Vignal‐Clermont, C., Montestruc, F., Taiel, M., & Sahel, J. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.10.002 · Cited by 22
Self-citationCapturing the Pattern of Transition From Carrier to Affected in Leber Hereditary Optic Neuropathy
Carbonelli, M., Morgia, C. L., Romagnoli, M., Amore, G., D'Agati, P., Valentino, M. L., Caporali, L., Cascavilla, M. L., Battista, M., Borrelli, E., et al. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.04.016 · Cited by 23
Zhang, H., Zhu, Y., Suehiro, Y., Mitani, S., & Xue, D. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2302490120 · Cited by 19
“Antioxidant therapies to prevent accumulation and damaging effects of reactive oxygen species due to compromised oxidative phosphorylation and analogs of coenzyme Q to improve the efficiency of the respiratory chain have been tested and have not shown satisfactory treatment outcomes (2, 62, 63).”
Perry, J. B., Davis, G. N., Allen, M. E., Makrecka‐Kuka, M., Dambrova, M., Grange, R. W., Shaikh, S. R., & Brown, D. A. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.08.010 · Cited by 22
Mejia-Vergara, A. J., Seleme, N., Sadun, A. A., & Karanjia, R. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01032-8 · Cited by 21
Metadata
- Authors
- Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., Kernt, M., Petraki, D., Rummey, C., Leinonen, M., Metz, G., Griffiths, P. G., Meier, T., & Chinnery, P. F.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- 2 Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Foundation Hospital, NE1 4LP, NHS Trust, UK
- Centre Hospitalier de l’Université de Montréal (CA)
- Royal Victoria Infirmary (GB)
- Santhera Pharmaceuticals (Switzerland) (CH)
- 8 4Pharma, Stockholm, 16440 Kista, Sweden
- Corresponding author
- Chinnery, Patrick F.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07-23
- Volume
- 134
- Issue
- 9
- Pages
- 2677-2686
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3170530
- OpenAlex
- W2124154990
- Cited by
- 578
- References
- 32
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 41 · 2023: 36 · 2022: 44 · 2021: 42 · 2020: 69 · 2019: 39 · 2018: 31 · 2017: 28 · 2016: 61 · 2015: 28 · 2014: 28 · 2013: 29 · 2012: 29
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Wellcome Trust (01GM0862)
- National Institute for Health and Care Research (NF-SI-0509-10011)
- Parkinson's UK
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung (01GM0862)
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- idebenone, Leber's hereditary optic neuropathy, mitochondrial DNA mutations, mitochondrial disease, visual acuity, retinal nerve fiber layer thickness, treatment response heterogeneity, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Aged, Antioxidants, DNA, Mitochondrial, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Placebos, Prospective Studies, Retina, Ubiquinone, Visual Acuity, Contrast Sensitivity, Optic Atrophy, Hereditary, Leber, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.